Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Retinal

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    631 result(s) found for: Retinal. Displaying page 6 of 32.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2014-002168-34 Sponsor Protocol Number: FNB-OK-2013-01 Start Date*: 2014-12-09
    Sponsor Name:Doc. MUDr. Petr Kolář, PhD, Oční klinika FN Brno
    Full Title: Study To Determine Efficacy of Aflibercept For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
    Medical condition: Retinal angiomatous proliferation secondary to wet age related macular degeneration.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    17.0 10015919 - Eye disorders 10069125 Retinal angiomatous proliferation LLT
    17.0 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002384-15 Sponsor Protocol Number: 3.0 Start Date*: 2014-10-23
    Sponsor Name:Universitätsklinik für Augenheilkunde und Optometrie
    Full Title: Intravitreal Aflibercept treatment in RAP-Lesions, PED, hemorrhagic CNV and PCV
    Medical condition: Exsudative Maculopathies
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10063381 Polypoidal choroidal vasculopathy PT
    17.0 10015919 - Eye disorders 10052501 Detachment of retinal pigment epithelium PT
    17.0 10015919 - Eye disorders 10069125 Retinal angiomatous proliferation LLT
    17.0 10015919 - Eye disorders 10060823 Choroidal neovascularisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006265-93 Sponsor Protocol Number: AVO1 Start Date*: 2009-03-11
    Sponsor Name:St Eriks Eye Hospital
    Full Title: A prospective, randomized, masked and controlled trial of intravitreal bevacizumab (Avastin®) for central retinal vein occlusion (CRVO).
    Medical condition: Central retinal vein occlusion (CRVO) is a sight-threatening ocular condition without efficient treatment.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001389-18 Sponsor Protocol Number: 1 Start Date*: 2006-09-27
    Sponsor Name:Ludwig Boltzmann Institute forRetinology and Biomicroscopic Laser Surgery
    Full Title: Comparison of Combined Therapy of Intravitreal Injection of Bevacizumab and Pegaptanib versus Mono-therapy (The MAAM Study)
    Medical condition: Subjects of either gender aged > 50 years, diagnosed with subfoveal CNV secondary to AMD, a predominantly occult lesion composition, and with best corrected visual acuity of 20/40 to 20/200 in the ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005601-22 Sponsor Protocol Number: poc1doxy Start Date*: 2008-03-27
    Sponsor Name:
    Full Title: Proof–of–concept study 1 (POC1): Evaluation of effect of doxycycline versus placebo on retinal function and posterior segment neovascularization in patients with severe non-proliferative or early ...
    Medical condition: Diabetic retinopathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012689 Diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022433-29 Sponsor Protocol Number: LATANO-2 Start Date*: 2010-10-13
    Sponsor Name:Aarhus University Hospital, Department of Ophthalmology
    Full Title: Pharmacological intervention on diabetic retinopathy with PGF
    Medical condition: Diabetic retinopathy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2022-001316-26 Sponsor Protocol Number: APHP200007 Start Date*: 2022-09-12
    Sponsor Name:Assistance Publique Hôpitaux de Paris / DRCI
    Full Title: Multicenter, randomized, prospective trial comparing the Efficacy and Safety of Adalimumab to that of Tocilizumab in severe uveitis of Behçet’s disease UVB Study
    Medical condition: severe uveitis of Behçet’s disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10071139 Behcet's uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000103-27 Sponsor Protocol Number: Eylea-2014 Start Date*: 2014-03-12
    Sponsor Name:
    Full Title: Plasma levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept in patients with exudative age-related macular degeneration.
    Medical condition: Exudative age-related macular degeneration (AMD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003967-21 Sponsor Protocol Number: MGT009 Start Date*: 2017-06-09
    Sponsor Name:MeiraGTx UK II Limited
    Full Title: An open label, multi-centre, Phase I/II dose escalation trial of a recombinant adeno-associated virus vector (AAV2/5-hRKp.RPGR) for gene therapy of adults and children with X-linked Retinitis Pigme...
    Medical condition: X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000425-31 Sponsor Protocol Number: MGT010 Start Date*: 2018-08-30
    Sponsor Name:MeiraGTx UK II Ltd
    Full Title: Long term follow-up study of participants following an open label, multicentre, Phase I/II dose escalation trial of a recombinant adeno-associated virus vector (AAV2/5-hRKp.RPGR) for gene therapy o...
    Medical condition: X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2005-006182-14 Sponsor Protocol Number: Start Date*: 2006-02-20
    Sponsor Name:UNIVERSITA DEGLI STUDI DI UDINE
    Full Title: Intravitreal Bevacizumab Avastin, Roche, United Kingdom for exudative maculopathies
    Medical condition: Exudative maculopathy associated with retinovascular disease
    Disease: Version SOC Term Classification Code Term Level
    6.1 10012689 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000379-41 Sponsor Protocol Number: RLBUHT3407 Start Date*: 2007-05-22
    Sponsor Name:Royal Liverpool & Broadgreen University hospital
    Full Title: Liverpool Avastin Dose Response and Retreatment Study
    Medical condition: Exudative senile macular degeneration of the retina
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-006063-22 Sponsor Protocol Number: FOM-ICI01-2011 Start Date*: 2012-02-03
    Sponsor Name:Fundación Oftalmológica del Mediterráneo
    Full Title: Prevención del edema macular diabético en pacientes con retinopatía diabética tratados con Ozurdex® tras la cirugía de cataratas
    Medical condition: edema macular diabético en pacientes con retinopatía diabética
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10025415 Macular oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-003556-31 Sponsor Protocol Number: SHP-607-201 Start Date*: 2015-02-10
    Sponsor Name:Premacure AB, A Member of the Shire Group of Companies
    Full Title: Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care
    Medical condition: Retinopathy of Prematurity (ROP)
    Disease:
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002132-29 Sponsor Protocol Number: ORH/PID/5336 Start Date*: 2008-01-29
    Sponsor Name:Oxford Radcliffe Hospitals NHS Trust
    Full Title: A Phase II Trial of Sorafenib (a tyrosine kinase inhibitor) given orally twice daily in renal cancer patients with vHL syndrome
    Medical condition: von Hippel Lindau syndrome (vHL) is a rare genetic disorder that causes a predisposition to develop multiple tumours, including renal, CNS and retinal tumours. vHL patients who have solid renal tu...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047716 Von Hippel-Lindau disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002656-24 Sponsor Protocol Number: CTSULENS1 Start Date*: 2018-01-23
    Sponsor Name:University of Oxford (Clinical Trials and Research Governance))
    Full Title: A randomised placebo-controlled clinical trial of fenofibrate to prevent progression of non-proliferative retinopathy in diabetes
    Medical condition: Diabetic retinopathy and diabetic maculopathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    20.0 10015919 - Eye disorders 10025425 Maculopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-003304-20 Sponsor Protocol Number: OKHN1006 Start Date*: 2012-07-02
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: Randomised Controlled Trial of Intravitreal therapy with Avastin compared to Observation in Patients with Diabetic Ischaemic Macular Oedema ‘The DIME study’
    Medical condition: Ischaemic Diabetic Macular Oedema
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    14.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    14.1 10015919 - Eye disorders 10012688 Diabetic retinal oedema PT
    14.1 10015919 - Eye disorders 10012661 Diabetic eye disease PT
    14.1 10015919 - Eye disorders 10054372 Diabetic retinal edema LLT
    14.1 10015919 - Eye disorders 10038925 Retinopathy diabetic LLT
    14.1 10015919 - Eye disorders 10057915 Diabetic macular oedema LLT
    14.1 10014698 - Endocrine disorders 10012657 Diabetic complications ophthalmic HLT
    14.1 10015919 - Eye disorders 10054109 Non-proliferative diabetic retinopathy LLT
    14.1 10014698 - Endocrine disorders 10012653 Diabetic complications HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000031-27 Sponsor Protocol Number: Start Date*: 2013-03-20
    Sponsor Name:Moorfields Eye Hospital
    Full Title: Intravitreal Ranibizumab (Lucentis) Therapy in Patients with Diabetic Ischaemic Macular Oedema (DIME)
    Medical condition: Ischaemic Diabetic Macular Oedema
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10057915 Diabetic macular oedema LLT
    14.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    14.1 10015919 - Eye disorders 10012688 Diabetic retinal oedema PT
    14.1 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    14.1 10015919 - Eye disorders 10054372 Diabetic retinal edema LLT
    14.1 10015919 - Eye disorders 10054109 Non-proliferative diabetic retinopathy LLT
    14.1 10015919 - Eye disorders 10012661 Diabetic eye disease PT
    14.1 10015919 - Eye disorders 10038925 Retinopathy diabetic LLT
    14.1 10014698 - Endocrine disorders 10012653 Diabetic complications HLGT
    14.1 10014698 - Endocrine disorders 10012657 Diabetic complications ophthalmic HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005081-19 Sponsor Protocol Number: 1 Start Date*: 2014-07-10
    Sponsor Name:HOSPICES CIVILS DELYON
    Full Title: Phase II study evaluating the efficacy of aflibercept for the treatment of idiopathic choroidal neovascularization in young subjects: the INTUITION study
    Medical condition: idiopathic choroidal neovascularization
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002944-28 Sponsor Protocol Number: DM2115403 Start Date*: 2012-02-17
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A phase 2, multi-national, multi-centre, double masked, randomised, placebo controlled, parallel-group study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficac...
    Medical condition: Diabetic macular edema with centre involvement
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 00:53:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA